Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Aptevo Research and Development LLC maintains 3 pending office actions in the Biotechnology & Pharmaceuticals sector. The prosecution work is spread across 2 distinct art units and involves 3 distinct examiners. This structure indicates that each examiner is currently handling a portion of the pending workload.
Elly Gerald Stoica serves as the busiest examiner for the company with 1 pending office action. Because the workload is distributed, each examiner manages an action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| HAM, JIEUN | 1 | 50.0% | +8.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17802927 | METHODS AND COMPOSITIONS FOR PREVENTING ADSORPTION OF THERAPEUTIC PROTEINS TO DRUG DELIVERY SYSTEM COMPONENTS | KIM, YUNSOO | 18d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17802927 | METHODS AND COMPOSITIONS FOR PREVENTING ADSORPTION OF THERAPEUTIC PROTEINS TO DRUG DELIVERY SYSTEM COMPONENTS | KIM, YUNSOO | 18d overdue |
| 18562725 | DOSING REGIMENS FOR PROTEIN THERAPEUTICS | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562725 | DOSING REGIMENS FOR PROTEIN THERAPEUTICS | STOICA, ELLY GERALD | — | §102§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 17802927 | METHODS AND COMPOSITIONS FOR PREVENTING ADSORPTION OF THERAPEUTIC PROTEINS TO DRUG DELIVERY SYSTEM COMPONENTS | KIM, YUNSOO | 1641 | §103§112 | Final Rejection | 18d overdue | Pending | Aug 26, 2022 |
| 17802920 | FORMULATIONS FOR PROTEIN THERAPEUTICS | HAM, JIEUN | 1643 | §102§103§112DP | Non-Final OA | — | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial